TY - JOUR
T1 - Cell-based cccDNA reporter assay combined with functional genomics identifies YBX1 as HBV cccDNA host factor and antiviral candidate target
AU - Verrier, Eloi R.
AU - Ligat, Gaëtan
AU - Heydmann, Laura
AU - Doernbrack, Katharina
AU - Miller, Julija
AU - Maglott-Roth, Anne
AU - Jühling, Frank
AU - El Saghire, Houssein
AU - Heuschkel, Margaux J.
AU - Fujiwara, Naoto
AU - Hsieh, Sen Yung
AU - Hoshida, Yujin
AU - Root, David E.
AU - Felli, Emanuele
AU - Pessaux, Patrick
AU - Mukherji, Atish
AU - Mailly, Laurent
AU - Schuster, Catherine
AU - Brino, Laurent
AU - Nassal, Michael
AU - Baumert, Thomas F.
N1 - © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.
PY - 2023/9/1
Y1 - 2023/9/1
N2 - Objectives Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and hepatocellular carcinoma. A key feature of HBV replication is the synthesis of the covalently close circular (ccc)DNA, not targeted by current treatments and whose elimination would be crucial for viral cure. To date, little is known about cccDNA formation. One major challenge to address this urgent question is the absence of robust models for the study of cccDNA biology. Design We established a cell-based HBV cccDNA reporter assay and performed a loss-of-function screen targeting 239 genes encoding the human DNA damage response machinery. Results Overcoming the limitations of current models, the reporter assay enables to quantity cccDNA levels using a robust ELISA as a readout. A loss-of-function screen identified 27 candidate cccDNA host factors, including Y box binding protein 1 (YBX1), a DNA binding protein regulating transcription and translation. Validation studies in authentic infection models revealed a robust decrease in HBV cccDNA levels following silencing, providing proof-of-concept for the importance of YBX1 in the early steps of the HBV life cycle. In patients, YBX1 expression robustly correlates with both HBV load and liver disease progression. Conclusion Our cell-based reporter assay enables the discovery of HBV cccDNA host factors including YBX1 and is suitable for the characterisation of cccDNA-related host factors, antiviral targets and compounds.
AB - Objectives Chronic hepatitis B virus (HBV) infection is a leading cause of liver disease and hepatocellular carcinoma. A key feature of HBV replication is the synthesis of the covalently close circular (ccc)DNA, not targeted by current treatments and whose elimination would be crucial for viral cure. To date, little is known about cccDNA formation. One major challenge to address this urgent question is the absence of robust models for the study of cccDNA biology. Design We established a cell-based HBV cccDNA reporter assay and performed a loss-of-function screen targeting 239 genes encoding the human DNA damage response machinery. Results Overcoming the limitations of current models, the reporter assay enables to quantity cccDNA levels using a robust ELISA as a readout. A loss-of-function screen identified 27 candidate cccDNA host factors, including Y box binding protein 1 (YBX1), a DNA binding protein regulating transcription and translation. Validation studies in authentic infection models revealed a robust decrease in HBV cccDNA levels following silencing, providing proof-of-concept for the importance of YBX1 in the early steps of the HBV life cycle. In patients, YBX1 expression robustly correlates with both HBV load and liver disease progression. Conclusion Our cell-based reporter assay enables the discovery of HBV cccDNA host factors including YBX1 and is suitable for the characterisation of cccDNA-related host factors, antiviral targets and compounds.
KW - antiviral therapy
KW - hepatitis B
UR - http://www.scopus.com/inward/record.url?scp=85168573030&partnerID=8YFLogxK
U2 - 10.1136/gutjnl-2020-323665
DO - 10.1136/gutjnl-2020-323665
M3 - 文章
C2 - 36591611
AN - SCOPUS:85168573030
SN - 0017-5749
VL - 72
SP - 1745
EP - 1757
JO - Gut
JF - Gut
IS - 9
ER -